[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SI0912558T1 - Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors - Google Patents

Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors

Info

Publication number
SI0912558T1
SI0912558T1 SI9730553T SI9730553T SI0912558T1 SI 0912558 T1 SI0912558 T1 SI 0912558T1 SI 9730553 T SI9730553 T SI 9730553T SI 9730553 T SI9730553 T SI 9730553T SI 0912558 T1 SI0912558 T1 SI 0912558T1
Authority
SI
Slovenia
Prior art keywords
pde
phosphodiesterase
tnf
inhibitors
type
Prior art date
Application number
SI9730553T
Other languages
English (en)
Slovenian (sl)
Inventor
Anthony Marfat
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of SI0912558T1 publication Critical patent/SI0912558T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI9730553T 1996-06-25 1997-06-02 Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors SI0912558T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2038596P 1996-06-25 1996-06-25
PCT/IB1997/000630 WO1997049702A1 (en) 1996-06-25 1997-06-02 Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors
EP97921992A EP0912558B1 (en) 1996-06-25 1997-06-02 Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors

Publications (1)

Publication Number Publication Date
SI0912558T1 true SI0912558T1 (en) 2003-10-31

Family

ID=21798354

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9730553T SI0912558T1 (en) 1996-06-25 1997-06-02 Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors

Country Status (43)

Country Link
US (1) US6040329A (zh)
EP (1) EP0912558B1 (zh)
JP (1) JP3152940B2 (zh)
KR (1) KR20000022516A (zh)
CN (1) CN1080260C (zh)
AP (1) AP1025A (zh)
AR (1) AR007456A1 (zh)
AT (1) ATE244713T1 (zh)
AU (1) AU716376B2 (zh)
BG (1) BG64052B1 (zh)
BR (1) BR9712782A (zh)
CA (1) CA2258285C (zh)
CO (1) CO4900056A1 (zh)
CZ (1) CZ423398A3 (zh)
DE (1) DE69723447T2 (zh)
DK (1) DK0912558T3 (zh)
DZ (1) DZ2254A1 (zh)
EA (1) EA002274B1 (zh)
ES (1) ES2201299T3 (zh)
GT (1) GT199700075A (zh)
HK (1) HK1018700A1 (zh)
HN (1) HN1997000079A (zh)
HR (1) HRP970350B1 (zh)
HU (1) HUP9903009A3 (zh)
ID (1) ID18579A (zh)
IL (1) IL127036A (zh)
IS (1) IS4910A (zh)
MA (1) MA24225A1 (zh)
MY (1) MY116915A (zh)
NO (1) NO986103L (zh)
NZ (1) NZ332752A (zh)
OA (1) OA10934A (zh)
PA (1) PA8432301A1 (zh)
PL (1) PL330974A1 (zh)
PT (1) PT912558E (zh)
SI (1) SI0912558T1 (zh)
SK (1) SK176598A3 (zh)
TN (1) TNSN97108A1 (zh)
TR (1) TR199802685T2 (zh)
TW (1) TW434237B (zh)
WO (1) WO1997049702A1 (zh)
YU (1) YU60198A (zh)
ZA (1) ZA975581B (zh)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2223920A3 (en) 1996-06-19 2011-09-28 Aventis Pharma Limited Substituted azabicyclic compounds
JP3554337B2 (ja) * 1996-09-04 2004-08-18 ファイザー・インク インダゾール誘導体、およびホスホジエステラーゼ（ｐｄｅ）タイプ４と腫瘍壊死因子（ｔｎｆ）産生の阻害剤としてのインダゾール誘導体の使用
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
AU754734B2 (en) * 1997-11-04 2002-11-21 Pfizer Products Inc. Indazole bioisostere replacement of catechol in therapeutically active compounds
ID24942A (id) * 1997-11-04 2000-08-31 Pfizer Prod Inc Senyawa terapi aktif yang berdasarkan penggantian bioisoster katekol dengan indazole pada inhibitor pde4
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
DE60018470T2 (de) * 1999-12-23 2006-02-16 Icos Corp., Bothell Cyclische amp spezifische phosphodiesterase inhibitoren
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
US7153871B2 (en) 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
DE60234510D1 (de) * 2001-04-16 2010-01-07 Eisai R&D Man Co Ltd 1h-indazolverbindungen die jnk hemmen
ATE374606T1 (de) 2001-12-14 2007-10-15 Serono Lab Verfahren zum herbeiführen eines eisprungs mittels eines nicht-polypeptid camp-level- modulators
WO2004009557A1 (en) 2002-07-19 2004-01-29 Memory Pharmaceuticals Corporation 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
AU2003256616B2 (en) 2002-07-19 2009-08-27 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
US7087625B2 (en) 2002-11-19 2006-08-08 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
MXPA05011200A (es) * 2003-04-18 2005-12-14 Memory Pharm Corp Derivados de pirazol como inhibidores de fosfodiesterasa 4.
US20090048255A1 (en) * 2003-07-21 2009-02-19 Schumacher Richard A Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
JP2008516964A (ja) 2004-10-15 2008-05-22 メモリー ファーマシューティカルス コーポレーション ホスホジエステラーゼ４阻害剤としてのピラゾール誘導体
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
WO2006129158A2 (en) * 2005-05-30 2006-12-07 Ranbaxy Laboratories Limited 3 - indazolyl - isoxazoline derivatives as inhibitors of phosphodiesterase type - i
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1928866A1 (en) * 2005-09-05 2008-06-11 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-iv
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2680625C (en) 2007-03-14 2016-02-23 Ranbaxy Laboratories Limited Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
US20100029689A1 (en) * 2008-07-02 2010-02-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CA2778949C (en) * 2009-10-30 2018-02-27 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as pde10 inhibitors
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
WO2015166370A1 (en) 2014-04-28 2015-11-05 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
KR20220167441A (ko) * 2021-06-11 2022-12-21 주식회사 메타센테라퓨틱스 신규한 인돌 유도체 및 이의 최종당화산물 관련 질환의 치료 용도
KR20220167804A (ko) * 2021-06-11 2022-12-22 주식회사 메타센테라퓨틱스 인돌 유도체를 포함하는 최종당화산물 관련 질환의 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB753573A (en) * 1953-06-17 1956-07-25 Ici Ltd New dyestuffs intermediates
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
TW223004B (zh) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
EP0633776B1 (en) * 1992-04-02 2001-05-09 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US5554620A (en) * 1993-09-14 1996-09-10 Sterling Winthrop Inc. Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
JPH07215952A (ja) * 1993-12-06 1995-08-15 Otsuka Pharmaceut Factory Inc カテコール誘導体
NZ292991A (en) * 1994-10-20 1999-02-25 Pfizer Bicyclic tetrahydropyrazolopyridines that are selective inhibitors of phosphodiesterase (pde) type iv or the production of tnf and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
SK176598A3 (en) 2000-06-12
EP0912558B1 (en) 2003-07-09
TR199802685T2 (xx) 1999-03-22
US6040329A (en) 2000-03-21
DK0912558T3 (da) 2003-08-18
JPH11514668A (ja) 1999-12-14
PA8432301A1 (es) 1999-12-27
BG103056A (en) 1999-10-29
WO1997049702A1 (en) 1997-12-31
CA2258285C (en) 2002-11-26
IS4910A (is) 1998-11-27
NZ332752A (en) 2001-04-27
BR9712782A (pt) 1999-12-07
CZ423398A3 (cs) 1999-12-15
HRP970350A2 (en) 1998-06-30
OA10934A (en) 2002-02-18
ATE244713T1 (de) 2003-07-15
MY116915A (en) 2004-04-30
CN1080260C (zh) 2002-03-06
GT199700075A (es) 1998-12-04
PL330974A1 (en) 1999-06-21
AR007456A1 (es) 1999-10-27
TNSN97108A1 (fr) 2005-03-15
NO986103D0 (no) 1998-12-23
PT912558E (pt) 2003-11-28
EA199801047A1 (ru) 1999-06-24
HRP970350B1 (en) 2003-04-30
HUP9903009A3 (en) 2002-01-28
BG64052B1 (bg) 2003-11-28
MA24225A1 (fr) 1997-12-31
ZA975581B (en) 1998-12-24
HN1997000079A (es) 1997-12-26
ID18579A (id) 1998-04-23
KR20000022516A (ko) 2000-04-25
AU716376B2 (en) 2000-02-24
CO4900056A1 (es) 2000-03-27
AU2785797A (en) 1998-01-14
HUP9903009A2 (hu) 2000-05-28
ES2201299T3 (es) 2004-03-16
JP3152940B2 (ja) 2001-04-03
HK1018700A1 (en) 1999-12-30
AP1025A (en) 2001-11-19
EP0912558A1 (en) 1999-05-06
DE69723447D1 (de) 2003-08-14
CN1223651A (zh) 1999-07-21
DZ2254A1 (fr) 2002-12-18
NO986103L (no) 1998-12-23
DE69723447T2 (de) 2003-12-24
IL127036A0 (en) 1999-09-22
CA2258285A1 (en) 1997-12-31
AP9701020A0 (en) 1997-07-31
TW434237B (en) 2001-05-16
EA002274B1 (ru) 2002-02-28
YU60198A (sh) 1999-09-27
IL127036A (en) 2001-06-14

Similar Documents

Publication Publication Date Title
IL127036A0 (en) Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors
PL332187A1 (en) Substitution derivatives of indazole and their application as inhibitors of phosphodiesterase (pde) of iv type and tumor necrosis factor (tnf)
IL152083A0 (en) Substituted indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and of the production of tumor necrosis factor (tnf)
SI1475377T1 (sl) Indolni derivati in njihova uporaba kot inhibitorji fosfodiesteraze 4
IL134013A (en) Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors
AU3102697A (en) Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
AU3588693A (en) N-benzyloxamic acid, oxamate, and oxamide derivatives and their use as TNF and PDE IV inhibitors
AU3885900A (en) Inhibitors of the egf-receptor tyrosine kinase and their use
IL114418A0 (en) Tumor necrosis factor receptor-II associated protein kinase and methods for its use
AU3094197A (en) Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
PL329855A1 (en) Inhibitors of s-cd23 formation and tumour necrosis factor release
AU4501199A (en) 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
ZA905593B (en) Tumor necrosis factor(tnf)inhibitor and method for obtaining the same